Apotex Inc. announced Wednesday that Apo-Semaglutide Injection is now shipping to wholesalers across Canada, with pharmacy availability expected within weeks. It is the commercial launch that follows from a remarkable regulatory opening: Canada became the first G7 country to approve generic semaglutide in April 2026 after Novo Nordisk failed to maintain a key Canadian patent covering acylated GLP-1 compounds.
The patent lapsed over an unpaid $188 maintenance fee. The window for reversal closed August 31, 2020. In the US, Japan, and Europe, Novo Nordisk’s active-ingredient protection for Ozempic runs to 2032 in the US and 2031 in Europe. American patients wait years longer for the same access Canada now has.
Two Generics Approved, More Coming
Health Canada approved the first generic semaglutide on April 28 from Dr. Reddy’s Laboratories, then approved Apotex three days later on May 1. Seven more applications, including from Sandoz, remain under review.
Apotex is the first to commercially launch. The company is also the only generic entrant offering both the 2 mg and 4 mg prefilled pen formats, matching every commercial SKU Novo Nordisk currently offers in the Canadian market. Developed with Orbicular Pharmaceutical Technologies, the product underwent Health Canada’s standard regulatory review for peptide medicines.
An estimated three million Canadian adults are currently taking GLP-1 medications like Ozempic. The pricing gap versus brand-name Ozempic is expected to be substantial. Indian generic semaglutide already sells for roughly $19 CAD per month; Canadian prices will be higher due to regulatory and distribution costs, but savings versus brand Ozempic should still be significant.
The Limitation That Matters
One boundary needs to be clear. Wegovy, semaglutide at the 2.4 mg weekly dose for obesity, remains patent-protected. Canadian prescribers writing off-label for weight loss on Ozempic will not find a cheaper legal pathway through this generic. Provincial plans covering diabetes indications will benefit. Weight loss patients will not.
Apo-Semaglutide Injection is approved for once-weekly treatment of adults with type 2 diabetes mellitus to improve glycemic control, in combination with diet and exercise. That is the indication. Weight loss is not.
What This Means Beyond Canada
The Canadian launch is an isolated case for now. The lapsed patent created a one-jurisdiction opening that no other G7 market currently has. Novo Nordisk still holds the compound patents in every other major market through at least 2031.
But the Canadian experience is being watched closely. It demonstrates that generic GLP-1 manufacturing at commercial scale is technically achievable, that regulatory review timelines can move quickly once the legal pathway opens, and that multiple manufacturers can enter simultaneously. When patents begin expiring in other markets after 2031, Canada is the proof-of-concept that the transition can work.
For now, Canadian patients with type 2 diabetes have a new option arriving on pharmacy shelves. Healthcare professionals should consult the complete Product Monograph before prescribing. This article does not constitute medical advice.
Sources
- Apotex Inc.
- Apotex Health Canada Approval Announcement
- Health Canada: Canada Approves Second Generic Semaglutide
- Drug Discovery Trends: Canada Approves Generic Semaglutide, a G7 First
- Clinical Trial Vanguard: Apotex Gets Health Canada Approval
- Walk-In: Generic Ozempic Canada Guide
- Semaglutide Canada: Generic Overview 2026
Editorial Disclosure
This article is based on a press release issued by Apotex Inc. and expanded with independent regulatory and market data. Apotex Inc. is a privately held company. No securities are discussed in this article. Apo-Semaglutide Injection is approved in Canada for once-weekly treatment of adults with type 2 diabetes mellitus only; it is not approved for weight management or obesity. This article does not constitute medical advice. Patients and healthcare professionals should consult the complete Product Monograph and a qualified healthcare provider before making any prescribing or treatment decisions. Drug pricing comparisons referenced are third-party estimates and subject to change. Regulatory timelines and additional generic approvals remain subject to Health Canada review. The information provided on this website is for informational and educational purposes only. Our content is derived strictly from verified online sources to ensure accuracy and objectivity. This analysis does not constitute financial, investment, or professional advice. Readers are encouraged to consult with qualified professionals before making decisions based on this information. For more information, please see our full DISCLAIMER.
